ADVENZYMES Advanced Enzyme Technologies Q4 FY26 results (Jan–Mar 2026) and concall
Advanced Enzyme Technologies reported record-high quarterly and annual revenues in Q4 and FY26, driven by broad-based growth across all segments and strong profitability. Q4 revenue reached INR 2,034 million (up 22% YoY) and annual revenue hit INR 7,458 million (up 17% YoY), with PAT growing 69% YoY in Q4. However, management highlighted potential near-term margin pressures from global inflation and geopolitical tensions, particularly in the challenging US market, and noted the cancellation of the interim dividend.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 33.3%, net profit up 100.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 77 | 101 | 87 | 125 | 116 +51% | 96 −5% | 116 +33% |
| EBITDA | 14 | 22 | 14 | 31 | 30 +114% | 23 +5% | 27 +93% |
| Net profit | 9 | 15 | 11 | 74 | 22 +144% | 13 −13% | 22 +100% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
